IP Library Patent Application 13160027
Patent Application
App. No. 13/160,027

Substituted Tetracycline Compounds as Synergistic Antifungal Agents

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/160,027
Abstract

The present invention relates to substituted tetracycline compounds and related methods for increasing the antifungal activity of an antifungal agent. The methods include administering to a subject an effective amount of a substituted tetracycline compound in combination with an antifungal agent such that the subject is treated for the fungal associated disorder.

Claims (40)

1 . A compound selected from the group consisting of:

and pharmaceutically acceptable salts and enantiomers thereof.

2 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

3 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

4 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

5 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

6 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

7 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

8 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

9 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

10 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

11 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

12 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

13 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

14 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

15 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

16 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

17 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

18 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

19 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

20 . The compound of claim 1 , wherein said compound is:

or a pharmaceutically acceptable salt or enantiomer thereof.

Assignments (2)
TERMINATION OF LIEN ON PATENTS Recorded Dec 23, 2014
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034700/0377 →
NOTICE Recorded Mar 8, 2013
From: PARATEK PHARMACEUTICALS, INC.
To: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC
Reel/Frame 029940/0106 →